caa a22 4500 605521298 CHVBK 20210128100739.0 cr unu---uuuuu 210128e20150301xx s 000 0 eng 10.1007/s00223-014-9926-8 doi (NATIONALLICENCE)springer-10.1007/s00223-014-9926-8 Prospect for Pharmacological Therapies to Treat Skeletal Muscle Dysfunction [Elektronische Daten] [Matthew Meriggioli, Ronenn Roubenoff] Skeletal muscle weakness is a leading cause of mobility disability in the elderly (sarcopenia), as a complication of acute or chronic illness (cachexia), and due to inherited or acquired muscle diseases (muscular dystrophies, myositides, etc.). As of now, there are no approved drugs that can reliably increase muscle strength and function. However, with our understanding of the regulation of myocyte signaling and homeostasis evolving rapidly, experimental treatments are now entering the clinic. We review the current status of clinical research in pharmacological therapies for muscle disorders. Springer Science+Business Media New York, 2014 Sarcopenia nationallicence Cachexia nationallicence Muscular dystrophies nationallicence Muscle wasting nationallicence Atrophy nationallicence Meriggioli Matthew Department of Musculoskeletal Translational Medicine, Novartis Institutes for Biomedical Research, 220 Massachusetts Avenue, 02139, Cambridge, MA, USA aut Roubenoff Ronenn Department of Musculoskeletal Translational Medicine, Novartis Institutes for Biomedical Research, 220 Massachusetts Avenue, 02139, Cambridge, MA, USA aut Calcified Tissue International Springer US; http://www.springer-ny.com 96/3(2015-03-01), 234-242 0171-967X 96:3<234 2015 96 223 https://doi.org/10.1007/s00223-014-9926-8 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00223-014-9926-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Meriggioli Matthew Department of Musculoskeletal Translational Medicine, Novartis Institutes for Biomedical Research, 220 Massachusetts Avenue, 02139, Cambridge, MA, USA aut NATIONALLICENCE 700 1- Roubenoff Ronenn Department of Musculoskeletal Translational Medicine, Novartis Institutes for Biomedical Research, 220 Massachusetts Avenue, 02139, Cambridge, MA, USA aut NATIONALLICENCE 773 0- Calcified Tissue International Springer US; http://www.springer-ny.com 96/3(2015-03-01), 234-242 0171-967X 96:3<234 2015 96 223